Trial Profile
A Phase 3, Intergroup Multicentre, Randomized, Controlled 3 Arm Parallel Group Study to Determine the Efficacy and Safety of Lenalidomide in Combination With Dexamethasone (RD) Versus Melphalan, Prednisone and Lenalidomide (MPR) Versus Cyclophosphamide, Prednisone and Lenalidomide (CPR) in Newly Diagnosed Elderly Multiple Myeloma Subjects.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Jul 2023
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Cyclophosphamide; Dexamethasone; Melphalan; Prednisone
- Indications Multiple myeloma
- Focus Therapeutic Use
- 30 Jun 2023 Planned End Date changed from 1 Nov 2022 to 1 Nov 2024.
- 08 Dec 2020 Results of a pooled analysis (of data pooled from IST-CAR-506, IST-CAR-561 EMN01, RV-MM-PI-0752 and RV-MM-EMN-441 studies)assessing the incidence of severe infections, presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology
- 05 Nov 2020 Planned End Date changed from 1 Nov 2017 to 1 Nov 2022.